Novato biotech Ultragenyx makes much more than expected in IPO, shares rise in debut

... is developing potential treatments for acute pain and heart failure. It will trade under the ticker symbol "TRVN." Shelton, Conn.-based Cara Therapeutics raised $55 million after pricing 5 million shares at $11 each. Cara focuses on pain treatments. ...



via Shelton Newswire http://ift.tt/1fstA8Q